Skip to main content
. 2022 Jul 13;108(4):276–281. doi: 10.1136/archdischild-2022-323905

Table 2.

Factors associated with an increased risk of relapse in Graves’ disease

Parameter type Factor
Clinical Younger age
Male*
Non-Caucasian ethnicity
Large goitre
No other autoimmune conditions
Biochemical More severe thyrotoxicosis at diagnosis
Immunological High TRAb level at diagnosis
High TRAb level on stopping ATD
Treatment course Shorter duration of ATD treatment
Genetic polymorphisms* eg, HLA subtypes (DB1*02, DQA1*05 and DRB1*03) and PTPN22 (rs2476601)

*In adult studies only.

ATD, antithyroid drug; HLA, human leucocyte antigen; PTPN22, protein tyrosine phosphatase non-receptor type 22; TRAb, thyroid receptor autoantibodies.